leisure time -WSS

leisure time

author：explore 2025-09-30 22:27:35 - browse：5

Vertex Pharmaceuticals - sunset — Bill Sikes/AP

LONDON — Regulators in the U.K. on Thursday approved a CRISPR-based medicine to treat both sickle cell disease and beta thalassemia, making it the world’s first therapy built on the revolutionary gene-editing technology and ushering in a new era of genetic medicine.

The authorization of the therapy, from Vertex Pharmaceuticals and CRISPR Therapeutics, is itself not a surprise. Clinical trials have shown the one-time treatment enabled many sickle cell patients to live free of debilitating pain crises and relieved thalassemia patients of needing regular blood transfusions, raising hopes that they have been effectively cured. But it also stands as a major achievement, coming just over a decade after the first and seminal lab experiments that showed CRISPR’s potential as a gene-editing tool were published.

In granting conditional approval to the therapy, which will have the brand name Casgevy and is also known as exa-cel, the U.K.’s Medicines and Healthcare products Regulatory Agency jumped ahead of its counterparts in the U.S. and Europe, which are also reviewing the medicine, in greenlighting the globe’s first CRISPR treatment. The MHRA’s authorization is for patients who are at least 12 years old.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Virtual care provider acquires bankrupt Pear's prescription apps

WSS

Mexico finds 491 migrants being held at vacant lot, almost all are from Guatemala

Paxlovid rebound happens. Why and to whom are still a mystery

Can sheer will power keep patients alive in their dying hours?

Doctors push to include dialysis machines in emergency stockpile

Google's generative AI to analyze medical images — and talk to docs

Why health care costs have stayed mostly flat since 2010

focus

leisure time

focus

Activists slam private health insurers over coverage restrictions

HCA sued by state AG for quality issues at Mission Health

Medical leaders decry Supreme Court decision on affirmative action

Sweden knocks USA out of World Cup in penalty kicks

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Medicare drug price negotiation hasn't dried up venture capital

Duchenne breakthrough therapy leaves behind pioneering families

Prime Medicine, Myeloid Therapeutics clash over genome

Sports medicine is finally prioritizing gender equality

Sage considers ways to reduce costs following FDA rejection

knowledge

Democrats are overperforming in 2023's special elections. Is it a clue for Biden vs. Trump?

Judge in Trump's classified documents case questions use of out

With heat waves through August, officials warn of health risks

Restaurant meals are packed with calories, and we still keep eating them

Prime Medicine, Myeloid Therapeutics clash over genome

With heat waves through August, officials warn of health risks

hotspot

Wikipedia

Wikipedia

focus